Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Leaderboard Analytics
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
Omnitracs, LLC et al v. Motive Technologies, Inc.
Case Number:
3:23-cv-05261
Court:
Nature of Suit:
Judge:
Firms
Companies
Sectors & Industries:
-
May 09, 2025
Motive Pushes Back At New-Trial Bid In Fleet Monitoring IP Fight
A fleet management company has hit back at arguments that it relied on making "improper religious and racial insinuations" to a jury to beat a rival's infringement claims, saying nothing that happened in the case warrants a new trial.
-
May 02, 2025
Omnitracs Alleges Religious Bias In IP Trial Tainted Outcome
A fleet management company relied on making "improper religious and racial insinuations" to a jury, along with other concerning behavior, in order to beat a rival's infringement claims, the patent owner told a California federal judge.
-
April 25, 2025
Motive Cleared Of Infringement In Fleet Monitoring IP Trial
A California federal jury has cleared Motive Technologies of allegations that it infringed a series of fleet monitoring patents in a case where the presiding judge has ordered further briefing on any patent eligibility issues.
-
April 10, 2025
IP Forecast: Novartis' Entresto Fight Heads To DC Circ.
Novartis will go before the D.C. Circuit next week in the latest legal front in the drug giant's battle to stop generic versions of its blockbuster heart failure drug Entresto. Here's a look at that case — plus all the other major intellectual property matters on deck in the coming week.